BioHarvest Sciences (BHST) News Today

Shares of BioHarvest Sciences Inc. (NASDAQ:BHST) are trading with mixed pressure today, as investors weigh fresh analyst earnings cuts against the company’s expansion into the high-growth fragrance market.

• Signed a new CDMO contract to develop a plant-based fragrance compound using its patented Botanical Synthesis technology, marking entry into the multi-billion-dollar scents industry.
• Announced that its CDMO division will leverage in-house AI tools for target discovery in the fragrance project, underlining technological leadership in plant-cell fermentation.
• Reported involvement in broader CDMO expansion into the fragrance market, showcasing a strategic pivot toward higher-margin applications beyond nutraceuticals.
• HC Wainwright reaffirmed its “Buy” rating and $14.00 price target on BHST despite trimming near-term estimates.
• Analyst projections still show a path to profitability, with EPS forecasts rising from break-even in 2025 to $1.19 by FY2029.
• HC Wainwright lowered its Q2 2025 EPS estimate to negative $0.11 from negative $0.10, reflecting continued operating losses.
• Analyst cut Q4 2025 EPS forecast to $0.00 from $0.01, signaling weaker-than-expected near-term performance.
• Consensus full-year 2025 earnings estimate remains a loss of $0.80 per share, underlining ongoing cash burn.